Fundamentals of stem cell mobilization for the heart: prospects for treating heart disease.
Despite significant advances in the detection, prevention and treatment of congestive heart failure, it remains a leading cause of morbidity and mortality. Recent research has revealed the potential role of stem and progenitor cells in repairing and regenerating damaged myocardium. A number of pharmacological agents that mobilize these cells, including granulocyte-colony stimulating factor, statins and AMD-3100, are currently under investigation. This review summarizes the rationale behind using these agents, as well as describing the preclinical and clinical data supporting their efficacy.
Rahman
Joseph E
JE
Cardiovascular Research Laboratories, UCLA School of Medicine, Los Angeles, CA 90095-1760, USA.
Maclellan
W Robb
WR
D000818:Animals; D001596:Benzylamines; D002317:Cardiovascular Agents / Q000494:pharmacology; D000080027:Cyclams; D042783:Endothelial Cells / Q000502:physiology; D006331:Heart Diseases / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006571:Heterocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000235:genetics / Q000502:physiology; D012038:Regeneration
D001596:Benzylamines; D002317:Cardiovascular Agents; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019718:Receptors, CXCR4; D016188:Receptors, Granulocyte Colony-Stimulating Factor; C088327:plerixafor